Briumvi (ublituximab-xiiy)



REFERRAL STATUS: □ New Referral □ Dose or Frequency Change □ Order Renewal

Infusion Office Preference:

PATIENT INFORMATION						
Date:	Patient Name:		DOB:	DOB:		
□ NKDA Allergies:		Weight (lbs / kg):		Height:		
Patient Status: ☐ New to T	herapy Continuing Therapy - Last	Treatment Date:	Next I	Due Date:		
PROVIDER INFORMATION						
Office Contact Name:	(Office Email:				
Prescribing Providers Name:		Provider NPI:				
Office Address:	dress: City: State:			Zip:		
Office Phone Number:	Office Fax Number:					
DIAGNOSIS AND ICD 10 CODE						
☐ Relapsing-Remitting m	ICD-10 Code:	G35.A				
☐ Active secondary progr	ICD-10 Code:	G35.C1				
REQUIRED DOCUMENTATION/Testing						
 □ This signed order form be □ Patient demographics A □ Clinical/Progress notes s □ Serum Quantitative In 	 □ Hepatitis B Test Results: Hep B surface Antigen & Hep B Core TOTAL Antibody □ Liver Function Test Results 					
Current MS treatment and end of current therapy date:						
PRE-MEDICATION ORDERS						
 □ acetaminophen (Tylenole diphenhydramine (Bena administered)) □ methylprednisolone (So □ other: 	ute is not circled PO will be	re p T <u>y</u>	lote: manufacturer ecommended remedication regimen is ylenol, Solu-Medrol and enadryl			
MEDICATION ORDERS						
Initial Dosing	☐ Briumvi 150 mg IV x 1 dose then 450 mg IV at week 2 (observe for one hour post infusion)					
Maintenance Dosing	☐ Briumvi 450 mg IV every 24 weeks (to begin 24 weeks from first infusion) Post-infusion monitoring of subsequent infusions is at the physician's discretion. Pt will be released after infusion unless observation time is requested by ordering MD.					
Other Dosing :	□ Briumvimg IV					
Refills*: None X1 year Other: *(if not indicated order will expire one year from date signed)						

SPECIAL INSTRUCTIONS

□ Urine pregnancy test prior to each infusion					
Provider Name (Print)	Physician Signature:	Date:			